Evidence map›Paper›PMID 17192894›Full record

ArticleAmerican journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics2007

Sensory gating and alpha-7 nicotinic receptor gene allelic variants in schizoaffective disorder, bipolar type.

Laura F Martin, Sherry Leonard, Mei-Hua Hall, Jason R Tregellas, Robert Freedman, Ann Olincy

Open access · greenAbstract read
In one paragraph

Article in American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 51 citations in OpenAlex.

  1. Novel drug treatments for schizophrenia.Nature reviews. Drug discovery · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Biomarkers of bipolar disorder: specific or shared with schizophrenia?Frontiers in bioscience (Elite edition) · 2013
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Laura F MartinDepartment of Psychiatry, Denver Veterans Affairs Medical Center, Denver, Colorado 80262, USA. laura.martin@uchsc.edu
Sherry Leonard
Mei-Hua Hall
Jason R Tregellas
Robert Freedman
Ann Olincy
University of Colorado Health · USDenver VA Medical Center · USKing's College London · GB

Funding

PHARMACOLOGY OF NICOTINIC RECEPTORSP50MH068582 · NIMH · UNIVERSITY OF COLORADO DENVER · PI FREEDMAN, ROBERT · 2004 to 2008
$9.4M
ELECTROPHYSIOLOGY OF SENSORY GATING IN SCHIZOPHRENIAR01MH038321 · NIMH · UNIVERSITY OF COLORADO DENVER · PI FREEDMAN, ROBERT · 1985 to 2004
$2.1M
ELECTROPHYSIOLOGY OF SENSORY GATING IN SCHIZOPHRENIAR37MH038321 · NIMH · UNIVERSITY OF COLORADO DENVER · PI FREEDMAN, ROBERT · 1990 to 1999
–
NIMH NIH HHS MH 38321NIMH NIH HHS P50 MH068582NIMH NIH HHS R01 MH038321NIMH NIH HHS R37 MH038321
6 · The paper itself

Abstract

objectivesSingle nucleotide allelic variants in the promoter region of the chromosome 15 alpha-7 acetylcholine nicotinic receptor gene (CHRNA7) are associated with both schizophrenia and the P50 auditory evoked potential sensory gating deficit. The purpose of this study was to determine if CHRNA7 promoter allelic variants are also associated with abnormal P50 ratios in persons with schizoaffective disorder, bipolar type.

methodsP50 auditory evoked potentials were recorded in a paired stimulus paradigm in 17 subjects with schizoaffective disorder, bipolar type. The P50 test to conditioning ratio was used as the measure of sensory gating. Mutation screening of the CHRNA7 promoter region was performed on the subjects' DNA samples. Comparisons to previously obtained data from persons with schizophrenia and controls were made.

resultsSubjects with schizophrenia, regardless of allele status, had an abnormal mean P50 ratio. Subjects with schizoaffective disorder, bipolar type and a variant allele had an abnormal mean P50 ratio, whereas those schizoaffective subjects with the common alleles had a normal mean P50 ratio. Normal control subjects had a normal mean ratio, but controls with variant alleles had higher P50 ratios.

conclusionsIn persons with bipolar type schizoaffective disorder, CHRNA7 promoter region allelic variants are linked to the capacity to inhibit the P50 auditory evoked potential and thus are associated with a type of illness genetically and biologically more similar to schizophrenia.

Indexed as

Promoter Regions, GeneticAdultalpha7 Nicotinic Acetylcholine ReceptorBipolar DisorderDiagnostic and Statistical Manual of Mental DisordersEvoked Potentials, AuditoryFemaleGenotypeHumansInterview, PsychologicalLod ScoreMaleMiddle AgedPolymorphism, GeneticPsychotic DisordersReceptors, Nicotinicalpha7 Nicotinic Acetylcholine ReceptorChrna7 protein, humanReceptors, Nicotinic

Identifiers

PMID17192894
PMCPMC3123155
OpenAlexW2128793894

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.